MX341866B - Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal. - Google Patents
Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.Info
- Publication number
- MX341866B MX341866B MX2012007882A MX2012007882A MX341866B MX 341866 B MX341866 B MX 341866B MX 2012007882 A MX2012007882 A MX 2012007882A MX 2012007882 A MX2012007882 A MX 2012007882A MX 341866 B MX341866 B MX 341866B
- Authority
- MX
- Mexico
- Prior art keywords
- gene expression
- renal cancer
- clinical outcome
- probability
- use gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N7/00—Computing arrangements based on specific mathematical models
- G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B99/00—Subject matter not provided for in other groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Data Mining & Analysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Mathematical Analysis (AREA)
- Artificial Intelligence (AREA)
- Probability & Statistics with Applications (AREA)
- Algebra (AREA)
- Computational Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29403810P | 2010-01-11 | 2010-01-11 | |
| US34623010P | 2010-05-19 | 2010-05-19 | |
| PCT/US2011/020596 WO2011085263A2 (en) | 2010-01-11 | 2011-01-07 | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012007882A MX2012007882A (es) | 2012-08-03 |
| MX341866B true MX341866B (es) | 2016-09-06 |
Family
ID=44258831
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007882A MX341866B (es) | 2010-01-11 | 2011-01-07 | Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal. |
| MX2016010666A MX375138B (es) | 2010-01-11 | 2011-01-07 | Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal. |
| MX2020009704A MX2020009704A (es) | 2010-01-11 | 2012-07-05 | Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010666A MX375138B (es) | 2010-01-11 | 2011-01-07 | Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal. |
| MX2020009704A MX2020009704A (es) | 2010-01-11 | 2012-07-05 | Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9551034B2 (enExample) |
| EP (5) | EP3029155A3 (enExample) |
| JP (5) | JP6286124B2 (enExample) |
| AU (1) | AU2011203977B2 (enExample) |
| CA (3) | CA3128103C (enExample) |
| DK (1) | DK3178944T3 (enExample) |
| ES (2) | ES3027507T3 (enExample) |
| IL (6) | IL219978A (enExample) |
| MX (3) | MX341866B (enExample) |
| NZ (4) | NZ600268A (enExample) |
| SG (1) | SG181806A1 (enExample) |
| WO (1) | WO2011085263A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3027507T3 (en) | 2010-01-11 | 2025-06-16 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| DK2598659T3 (en) | 2010-07-27 | 2015-05-26 | Genomic Health Inc | PROCEDURE FOR USING GENEPRESSION FOR DETERMINING PROSTATE CANCER FORECAST |
| EP2603622A4 (en) | 2010-08-13 | 2015-04-22 | Somalogic Inc | BIOMARKERS FOR PANCREATIC CANCER AND USES THEREOF |
| WO2013016673A2 (en) * | 2011-07-27 | 2013-01-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma |
| EP2748356A2 (en) * | 2011-08-22 | 2014-07-02 | Somalogic, Inc. | Renal cell carcinoma biomarkers and uses thereof |
| HK1212389A1 (en) | 2011-10-24 | 2016-06-10 | Signalchem Lifesciences Corporation | Carbonic anhydrase ix-related markers and use thereof |
| CA2863040C (en) | 2012-01-31 | 2022-04-19 | Genomic Health, Inc. | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| CA2903878C (en) * | 2013-05-30 | 2020-10-27 | Genomic Health, Inc. | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
| WO2015050500A1 (en) | 2013-09-17 | 2015-04-09 | Agency For Science, Technology And Research | Multigene assay for prognosis of renal cancer |
| US10731163B2 (en) * | 2014-09-02 | 2020-08-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Oligonucleotide targeted to the A20-3′ untranslated region |
| JP6638128B2 (ja) * | 2014-10-30 | 2020-01-29 | 公立大学法人福島県立医科大学 | 腎がんの悪性度の検査マーカー及び検査方法 |
| US20180044736A1 (en) * | 2015-02-03 | 2018-02-15 | Cedars-Sinai Medical Center | Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer |
| GB201616912D0 (en) | 2016-10-05 | 2016-11-16 | University Of East Anglia | Classification of cancer |
| CA3052670A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2018161027A1 (en) * | 2017-03-03 | 2018-09-07 | Oregon State University | Antisense antibacterial compounds and methods |
| US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| US11335464B2 (en) * | 2018-01-12 | 2022-05-17 | Siemens Medical Solutions Usa, Inc. | Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making |
| CA3105292A1 (en) * | 2018-08-10 | 2020-02-13 | Omniseq, Inc. | Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade |
| WO2020085936A1 (ru) * | 2018-10-24 | 2020-04-30 | Общество С Ограниченной Ответственностью "Онкобокс" | Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки |
| MX2021008797A (es) | 2019-01-23 | 2022-01-31 | Regeneron Pharma | Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7). |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| US20220364178A1 (en) * | 2019-08-14 | 2022-11-17 | University Of Massachusetts | Urinary rna signatures in renal cell carcinoma (rcc) |
| EP4298219A1 (en) | 2021-02-26 | 2024-01-03 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
| CN113025716A (zh) * | 2021-03-02 | 2021-06-25 | 北京大学第一医院 | 一种用于人肿瘤分级的基因组合及其用途 |
| CN113817816A (zh) * | 2021-10-08 | 2021-12-21 | 济南艾迪康医学检验中心有限公司 | 检测epas1基因突变的引物、试剂盒和方法 |
| WO2023080900A1 (en) * | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| CN118711678B (zh) * | 2024-08-22 | 2025-12-12 | 暨南大学附属第一医院（广州华侨医院） | 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US7135314B1 (en) | 1997-04-17 | 2006-11-14 | Cell Therapeutics, Inc. | Human phosphatidic acid phosphatase |
| DE60137829D1 (de) * | 2000-01-13 | 2009-04-16 | Genentech Inc | Menschliche stra6 polypeptide |
| DE10126344A1 (de) | 2000-07-14 | 2002-01-24 | Max Planck Gesellschaft | Apoptose-induzierende DNA-Sequenzen |
| AU2001294842A1 (en) * | 2000-09-28 | 2002-04-08 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
| AU2002254482A1 (en) * | 2001-03-19 | 2002-10-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
| WO2002079411A2 (en) * | 2001-03-29 | 2002-10-10 | Van Andel Institute | Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification |
| DE60239535D1 (de) | 2001-06-18 | 2011-05-05 | Rosetta Inpharmatics Llc | Diagnose und prognose von brustkrebspatientinnen |
| US7470509B2 (en) * | 2002-02-08 | 2008-12-30 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer |
| DK2258872T3 (da) | 2002-03-13 | 2013-11-18 | Genomic Health Inc | Genekspressionsprofilering i biopsier af tumorvæv |
| US20060183120A1 (en) | 2002-10-04 | 2006-08-17 | Teh Bin T | Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers |
| AU2003298689A1 (en) | 2002-11-21 | 2004-06-18 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| CA2523798A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
| EP3170906B1 (en) | 2003-06-24 | 2018-08-22 | Genomic Health, Inc. | Prediction of likelihood of cancer recurrence |
| EP1644522A2 (en) | 2003-07-02 | 2006-04-12 | Novartis AG | Genes regulated in ovarian cancer as prognostic and therapeutic targets |
| US20050002904A1 (en) * | 2003-07-03 | 2005-01-06 | Wary Kishore K. | Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
| EP3330875B1 (en) | 2003-07-10 | 2021-12-01 | Genomic Health, Inc. | Expression profile algorithm and test for prognosing breast cancer recurrence |
| US20050130193A1 (en) | 2003-09-10 | 2005-06-16 | Luxon Bruce A. | Methods for detecting, diagnosing and treating human renal cell carcinoma |
| JP2005211023A (ja) | 2004-01-30 | 2005-08-11 | Hayashibara Biochem Lab Inc | 腎細胞癌の転移若しくは再発の可能性を予測する方法 |
| US20070224596A1 (en) * | 2004-04-09 | 2007-09-27 | Mariana Nacht | Compositions and methods for the modifying hypoxia induced gene regulation |
| US7871769B2 (en) | 2004-04-09 | 2011-01-18 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| AU2005249446A1 (en) * | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Biomarkers for monitoring inhibition of IMPDH pathway |
| US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| WO2006066071A2 (en) * | 2004-12-17 | 2006-06-22 | Mayo Foundation For Medical Education And Research | Prognosis of renal cell carcinoma |
| AU2006210794A1 (en) * | 2005-02-01 | 2006-08-10 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Biomarkers for tissue status |
| RU2007129864A (ru) * | 2005-02-18 | 2009-03-27 | Вайет (Us) | Фармакогеномные маркеры для прогнозирования солидных опухолей |
| WO2006124836A1 (en) | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
| WO2006124022A1 (en) | 2005-05-13 | 2006-11-23 | Vanandel Research Institute | Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma |
| US20070037186A1 (en) * | 2005-05-20 | 2007-02-15 | Yuqiu Jiang | Thyroid fine needle aspiration molecular assay |
| AU2006254834B2 (en) | 2005-06-08 | 2012-09-20 | Millennium Pharmaceuticals, Inc. | Treatment of patients with cancer therapy |
| US20070105133A1 (en) | 2005-06-13 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| ES2338699T3 (es) | 2005-06-15 | 2010-05-11 | Pfizer Limited | Arilpirazoles sustituidos para uso contra parasitos. |
| JP5435529B2 (ja) | 2005-09-02 | 2014-03-05 | 東レ株式会社 | 腎ガン診断、腎ガン患者予後予測のための組成物および方法 |
| CN101292046B (zh) | 2005-09-14 | 2013-03-13 | 人类遗传标记控股有限公司 | 健康状态的测定法 |
| EP2332984A3 (en) | 2005-09-30 | 2011-10-12 | Universiteit Maastricht | Tumor angiogenesis associated genes and a method for their identification |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| CA2633593A1 (en) | 2005-12-16 | 2007-10-04 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
| US20080242606A1 (en) * | 2006-06-06 | 2008-10-02 | Zhong Jiang | Use of IMP3 as a Prognostic Marker for Cancer |
| AU2007284724B2 (en) * | 2006-08-10 | 2014-03-13 | Millennium Pharmaceuticals, Inc. | For the identification, assessment, and treatment of patients with cancer therapy |
| US8450057B2 (en) | 2006-08-14 | 2013-05-28 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| WO2008083098A1 (en) | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Agents for reversing epigenetic silencing of genes |
| US20080286273A1 (en) | 2007-05-02 | 2008-11-20 | Siemens Medical Solutions Usa, Inc. | Knowledge-Based Proliferation Signatures and Methods of Use |
| EP1990417A1 (en) | 2007-05-11 | 2008-11-12 | Universität Bayreuth | Archaeal plasmid vector system |
| WO2009105640A1 (en) | 2008-02-22 | 2009-08-27 | Virginia Commonwealth University | Signatures associated with rejection or recurrence of cancer |
| GB2512153B (en) | 2008-11-17 | 2014-11-12 | Veracyte Inc | Methods and compositions of molecular profiling for disease diagnostics |
| CA2766703A1 (en) * | 2009-06-26 | 2010-12-29 | Noviogendix Research B.V. | Molecular markers in kidney cancer |
| MX337650B (es) | 2009-11-23 | 2016-03-14 | Genomic Health Inc | Metodos para predecir el desenlace clinico del cancer. |
| ES3027507T3 (en) | 2010-01-11 | 2025-06-16 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| KR20140072014A (ko) | 2011-06-16 | 2014-06-12 | 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. | 생물지표 조성물 및 방법 |
| EP2748356A2 (en) | 2011-08-22 | 2014-07-02 | Somalogic, Inc. | Renal cell carcinoma biomarkers and uses thereof |
-
2011
- 2011-01-07 ES ES20210111T patent/ES3027507T3/es active Active
- 2011-01-07 MX MX2012007882A patent/MX341866B/es active IP Right Grant
- 2011-01-07 CA CA3128103A patent/CA3128103C/en active Active
- 2011-01-07 US US12/987,023 patent/US9551034B2/en active Active
- 2011-01-07 DK DK17153152.8T patent/DK3178944T3/da active
- 2011-01-07 EP EP15203193.6A patent/EP3029155A3/en not_active Withdrawn
- 2011-01-07 AU AU2011203977A patent/AU2011203977B2/en active Active
- 2011-01-07 CA CA3256492A patent/CA3256492A1/en active Pending
- 2011-01-07 EP EP11732245.3A patent/EP2524055A4/en not_active Withdrawn
- 2011-01-07 NZ NZ600268A patent/NZ600268A/en unknown
- 2011-01-07 EP EP17153152.8A patent/EP3178944B1/en active Active
- 2011-01-07 EP EP20210111.9A patent/EP3831964B1/en active Active
- 2011-01-07 NZ NZ719474A patent/NZ719474A/en unknown
- 2011-01-07 NZ NZ705645A patent/NZ705645A/en unknown
- 2011-01-07 SG SG2012045142A patent/SG181806A1/en unknown
- 2011-01-07 JP JP2012548188A patent/JP6286124B2/ja active Active
- 2011-01-07 CA CA2783858A patent/CA2783858C/en active Active
- 2011-01-07 WO PCT/US2011/020596 patent/WO2011085263A2/en not_active Ceased
- 2011-01-07 NZ NZ61700311A patent/NZ617003A/en unknown
- 2011-01-07 ES ES17153152T patent/ES2741379T3/es active Active
- 2011-01-07 EP EP19173150.4A patent/EP3561078A1/en not_active Withdrawn
- 2011-01-07 MX MX2016010666A patent/MX375138B/es unknown
-
2012
- 2012-05-24 IL IL219978A patent/IL219978A/en active IP Right Grant
- 2012-07-05 MX MX2020009704A patent/MX2020009704A/es unknown
-
2016
- 2016-03-04 JP JP2016041689A patent/JP2016174600A/ja active Pending
- 2016-12-05 US US15/368,979 patent/US10892038B2/en active Active
-
2017
- 2017-04-06 IL IL251635A patent/IL251635B/en active IP Right Grant
- 2017-04-14 JP JP2017080314A patent/JP6546214B2/ja active Active
- 2017-12-14 IL IL256335A patent/IL256335B/en active IP Right Grant
-
2018
- 2018-10-03 IL IL26210018A patent/IL262100B/en active IP Right Grant
-
2019
- 2019-06-20 JP JP2019114273A patent/JP7307602B2/ja active Active
- 2019-10-24 IL IL270151A patent/IL270151B/en active IP Right Grant
-
2020
- 2020-11-19 US US16/952,566 patent/US11776664B2/en active Active
-
2021
- 2021-02-07 IL IL280689A patent/IL280689B/en unknown
- 2021-07-06 JP JP2021112234A patent/JP7385630B2/ja active Active
-
2023
- 2023-08-23 US US18/454,312 patent/US12412642B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ705645A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| Crea et al. | Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer | |
| WO2013009655A3 (en) | Uses of labeled hsp90 inhibitors | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| MX2016011612A (es) | Determinacion de agresividad, pronostico y responsividad del cancer al tratamiento. | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| MX366164B (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| EA201200101A1 (ru) | Способ прогнозирования эффективности лекарственных соединений для пациента | |
| CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| WO2014140933A8 (en) | Method for the prognosis and treatment of cancer metastasis | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| HK1213946A1 (zh) | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 | |
| NZ748624A (en) | Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells | |
| WO2008037700A3 (en) | Methods for breast cancer prognosis | |
| WO2014139885A3 (en) | Molecular targets and inhibitors of said targets, useful in the treatment of diseases associated with epithelial mesenchymal transition | |
| WO2012154567A3 (en) | Human invasion signature for prognosis of metastatic risk | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| CY1119430T1 (el) | Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου | |
| Lee et al. | Comparing the secretomes of chemorefractory and chemoresistant ovarian cancer cell populations | |
| GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| WO2013188823A3 (en) | Cancer prognostic assays | |
| RU2010123021A (ru) | Способ диагностики рака молочной железы по уровню рнк интерлейкинов il-8 и/или il-18 в плазме крови | |
| RU2014128454A (ru) | Способ определения вероятности рецидивирования рака молочной железы | |
| MX2013013153A (es) | La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |